One year after the first reported case of COVID-19 in Portugal, on the 2nd of March 2020, we are acquiring knowledge at an unprecedented pace on this new infectious disease caused by the newly emerged SARS-CoV-2 virus. We are just at the tip of the iceberg, but the breakthroughs have been substantial. Notably, a continuous sequencing characterization of the viral genome is allowing a timely monitoring of new variants, informing public health actions. Machine learning methods and large clinical trials are being conducted for drug repurposing, leading to the identification of widely available treatment drugs, such as tocilizumab and sarilumab.

Click here for the full paper.